PEDIARIX: clinical trials.
PEDIARIX is the first pentavalent combination vaccine licensed for use in infants in the USA. This vaccine is indicated for the prevention of diphtheria, tetanus, pertussis, hepatitis B and poliovirus. This article reviews the available data regarding the vaccine's immunogenicity and safety.
Yeh
Sylvia H
SH
UCLA Center for Vaccine Research, Los Angeles Biomedical Research Institute at Harbor-UCLA, 1124 W. Carson St, Liu Research Building, Torrance, CA 90502, USA. syeh@uclacvr.labiomed.org
D002986:Clinical Trials as Topic; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D017325:Hepatitis B Vaccines; D006801:Humans; D007223:Infant; D011054:Poliovirus Vaccine, Inactivated; D017778:Vaccines, Combined / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D017325:Hepatitis B Vaccines; C472675:PEDIARIX; D011054:Poliovirus Vaccine, Inactivated; D017778:Vaccines, Combined